These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 6066599)

  • 1. An investigation of the assay of heparin based on its activity in vivo.
    Rezansoff WE; Jaques LB
    Thromb Diath Haemorrh; 1967 Aug; 18(1-2):150-60. PubMed ID: 6066599
    [No Abstract]   [Full Text] [Related]  

  • 2. Variability of heparin preparations in clinical use.
    Jaques LB; Kavanagh LW
    Thromb Diath Haemorrh Suppl; 1973; 56():171-80. PubMed ID: 4142115
    [No Abstract]   [Full Text] [Related]  

  • 3. Characterization of a new potent heparin. 6th communication: The comparison of the anticoagulant effect of the sodium and calcium salts of a new potent heparin after s.c. injection in beagle dogs.
    Bhargava AS; Schöbel C; Günzel P
    Arzneimittelforschung; 1981; 31(1):79-82. PubMed ID: 7194097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies in man and experimental animals of a low molecular weight heparin fraction.
    Thomas DP; Merton RE; Lewis WE; Barrowcliffe TW
    Thromb Haemost; 1981 Jun; 45(3):214-8. PubMed ID: 7281101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a new potent heparin. 1 communication: Determinations of anticoagulant activity of a high potency heparin preparation in vivo using dog as an experimental animal and in vitro using dog and human plasma.
    Bhargava AS; Heinick J; Schöbel C; Günzel P
    Arzneimittelforschung; 1980; 30(6):993-6. PubMed ID: 7191280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated coagulation time in monitoring heparinized dogs.
    Green RA
    Am J Vet Res; 1980 Nov; 41(11):1793-7. PubMed ID: 7212408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a new potent heparin. 7th communication: A comparative study of a new potent heparin in human after i.v. application.
    Bhargava AS; Wendt H; Günzel P
    Arzneimittelforschung; 1981; 31(2):386-8. PubMed ID: 7194658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-hemostatic action of heparin: relationship between topical and intravenous application.
    Magalhàes JR; Unglert CV; Damiani H; Nogueira Filho J
    Acta Physiol Lat Am; 1971; 21(3):209-15. PubMed ID: 5158678
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of instruments on lupus anticoagulant testing.
    Exner T; Hohnen-Behrens C; Newman P; Dargan W
    Thromb Haemost; 2000 Feb; 83(2):345-8. PubMed ID: 10739397
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of point-of-care activated partial thromboplastin time testing by comparison to laboratory-based assay for control of intravenous heparin.
    Douglas AD; Jefferis J; Sharma R; Parker R; Handa A; Chantler J
    Angiology; 2009; 60(3):358-61. PubMed ID: 19398428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of heparin administration on the plasma protein binding and disposition of propranolol.
    Silber B; Lo M; Riegelman S
    Res Commun Chem Pathol Pharmacol; 1980 Mar; 27(3):419-29. PubMed ID: 7384636
    [No Abstract]   [Full Text] [Related]  

  • 13. Anticoagulating and non-enzymatic fibrinolytic activities of heparin-antithrombin III and antithrombin III-heparin-thrombin complexes in vitro and in vivo.
    Kudrjashov BA; Pastorova VE; Lyapina LA
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(5):731-42. PubMed ID: 6198257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of protamine of the prolonged response to intrapulmonary heparin.
    Wright CJ; Mahadoo J; Jaques LB
    Can J Surg; 1981 Mar; 24(2):130-2. PubMed ID: 7225967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man.
    Hansen JB; Sandset PM; Huseby KR; Huseby NE; Nordøy A
    Thromb Haemost; 1996 Nov; 76(5):703-9. PubMed ID: 8950777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated partial thromboplastin time and activated coagulation time in monitoring heparinized cats.
    Greene CE; Meriwether E
    Am J Vet Res; 1982 Aug; 43(8):1473-7. PubMed ID: 7103231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of gentamicin on heparin activity.
    Tyler LS; Rehder TL; Davis RB
    Am J Hosp Pharm; 1981 Apr; 38(4):537-40. PubMed ID: 7282683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative multicenter study of a rabbit high-sensitivity thromboplastin and a recombinant thromboplastin with synthetic phospholipids].
    Martínez-Brotóns F; Borrell M; Fontcuberta J; Batlle J; López F; Páramo JA; Ribera C; Rocha E; Vicente V; Zuazu I
    Sangre (Barc); 1994 Aug; 39(4):245-51. PubMed ID: 7985052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystallization of heparin as the barium salt for standardization purposes.
    Kavanagh LW; Jaques LB
    Arzneimittelforschung; 1974 Dec; 24(12):1942-5. PubMed ID: 4480274
    [No Abstract]   [Full Text] [Related]  

  • 20. The heparin target organ--the endothelium. Studies in a rat model.
    Hiebert LM; Wice SM; McDuffie NM; Jaques LB
    Q J Med; 1993 May; 86(5):341-8. PubMed ID: 8327652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.